Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
Stopped early · Phase 1/Phase 2
Conditions studied: Non-Hodgkin's Lymphoma (NHL)
In brief
Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Motexafin gadolinium may increase the effectiveness of yttrium Y 90 ibritumomab tiuxetan by making the cancer cells more sensitive to the drug. This phase I/II trial is studying the side effects and best dose of motexafin gadolinium when administered with rituximab and yttrium Y 90 ibritumomab tiuxetan and to see how well they work in treating patients with stage II, stage III, or stage IV relapsed or refractory non-Hodgkin's lymphoma.
Key facts
- Study ID
- NCT00089284
- Run by
- Northwestern University
- People needed
- 30
- Starts
- 2003-10-28
- Expected to finish
- 2008-08-20
- Last updated by the study team
- 2019-08-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- No major bleeding within the past 4 weeks No uncontrolled hypertension No stroke within the past 4 weeks
- No active infection
- No other active nonmalignant disease
- No known G6PD deficiency
- No history of porphyria
- No other condition that would preclude study participation
- No human anti-mouse antibodies
- No known history of HIV
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior radioimmunoconjugate therapy
- No prior exposure to murine antibodies other than rituximab
- More than 4 weeks since prior rituximab
- No history of failed stem cell collection
Where it is running
- Northwestern University — Chicago, Illinois, United States
- Jesse B. Brown Veterans Affairs Medical Center — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.